Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Dividends Paid - CommonFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cryo Cell International (CCEL) Net Income (2016 - 2025)

Historic Net Income for Cryo Cell International (CCEL) over the last 16 years, with Q3 2025 value amounting to $749408.0.

  • Cryo Cell International's Net Income fell 2874.18% to $749408.0 in Q3 2025 from the same period last year, while for Aug 2025 it was -$788541.0, marking a year-over-year increase of 9116.61%. This contributed to the annual value of $87121.0 for FY2024, which is 10091.5% up from last year.
  • Cryo Cell International's Net Income amounted to $749408.0 in Q3 2025, which was down 2874.18% from $355785.0 recorded in Q2 2025.
  • In the past 5 years, Cryo Cell International's Net Income ranged from a high of $1.2 million in Q2 2021 and a low of -$11.2 million during Q4 2023
  • In the last 5 years, Cryo Cell International's Net Income had a median value of $634719.0 in 2022 and averaged -$380122.2.
  • As far as peak fluctuations go, Cryo Cell International's Net Income tumbled by 586362.04% in 2023, and later surged by 19676.98% in 2024.
  • Quarter analysis of 5 years shows Cryo Cell International's Net Income stood at -$3.6 million in 2021, then soared by 94.85% to -$187638.0 in 2022, then crashed by 5863.62% to -$11.2 million in 2023, then surged by 80.55% to -$2.2 million in 2024, then skyrocketed by 134.43% to $749408.0 in 2025.
  • Its Net Income was $749408.0 in Q3 2025, compared to $355785.0 in Q2 2025 and $282855.0 in Q1 2025.